Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
Eike Sebastian DebusMark R NehlerNicholas GovsyeyevRupert M BauersachsSonia S AnandManesh R PatelFabrizio FanelliWarren H CapellTaylor BrackinFranz HinterreiterDainis KrievinsPatrice NaultGabriele PiffarettiAlexei SvetlikovNicole JaegerConnie N HessHenrik H SillesenMichael ConteJoseph L MillsEva MuehlhoferLloyd P HaskellScott D BerkowitzWilliam R HiattMarc P BonacaPublished in: Circulation (2021)
The efficacy of rivaroxaban is associated with a benefit in patients who underwent surgical LER. Although bleeding was increased with rivaroxaban plus aspirin, the incidence was low, with no significant increase in fatal bleeding, intracranial hemorrhage, or postprocedural bleeds requiring intervention. Registration: URL: http://www.clinicaltrials.gov; Unique Identifier: NCT02504216.
Keyphrases
- atrial fibrillation
- venous thromboembolism
- peripheral artery disease
- low dose
- pulmonary embolism
- end stage renal disease
- ejection fraction
- randomized controlled trial
- newly diagnosed
- chronic kidney disease
- cardiovascular events
- clinical trial
- prognostic factors
- study protocol
- risk factors
- phase iii
- patient reported outcomes
- phase ii
- acute coronary syndrome
- optic nerve